Acrodermatitis continua of Hallopeau: clinical perspectives

References

• Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002;3(6):389–400. doi:10.2165/00128071-200203060-0000312113648
   PubMedGoogle Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144. doi:10.2147/PTT.S9895429387600
   PubMed Web of Science ®Google Scholar
• Jo SJ, Park JY, Yoon HS, Youn JI. Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol. 2006;33(11):787–791. doi:10.1111/j.1346-8138.2006.00180.x17073995
   PubMed Web of Science ®Google Scholar
• Waller JM, Wu JJ, Murase JE, Dyson SW, Kelly KM. Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau. Clin Exp Dermatol. 2007;32(5):619–620. doi:10.1111/j.1365-2230.2007.02440.x17501968
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol. 2011;50(10):1195–1211. doi:10.1111/j.1365-4632.2011.04993.x21950286
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. doi:10.1111/jdv.1438628585342
   PubMed Web of Science ®Google Scholar
• Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645–1651. doi:10.1111/jdv.1494929573491
   PubMed Web of Science ®Google Scholar
• Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018;178(3):614–618. doi:10.1111/bjd.1623229333670
   PubMed Web of Science ®Google Scholar
• Yerushalmi J, Grunwald MH, Hallel-Halevy D, Avinoach I, Halevy S. Chronic pustular eruption of the thumbs. Diagnosis: acrodermatitis continua of Hallopeau (ACH). Arch Dermatol. 2000;136(7):925–930.
   Google Scholar
• Abbas O, Itani S, Ghosn S, et al. Acrodermatitis continua of Hallopeau is a clinical phenotype of DITRA: evidence that it is a variant of pustular psoriasis. Dermatology. 2013;226(1):28–31. doi:10.1159/000346572
   Web of Science ®Google Scholar
• Rosenberg BE, Strober BE. Acrodermatitis continua. Dermatol Online J. 2004;10(3):9.
   Google Scholar
• Korman AM, Rzepka PV, Sopkovich JA. Acrodermatitis continua of Hallopeau. JAMA Dermatol. 2018;154(11):1346. doi:10.1001/jamadermatol.2017.619530285064
   PubMed Web of Science ®Google Scholar
• Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510–518. doi:10.1016/j.clindermatol.2007.08.00318021886
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437. doi:10.1016/j.ajhg.2011.07.02221839423
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628. doi:10.1056/NEJMoa101306821848462
   PubMed Web of Science ®Google Scholar
• O’Keefe E, Braverman IM, Cohen I. Annulus migrans. Identical lesions in pustular psoriasis, Reiter’s syndrome, and geographic tongue. Arch Dermatol. 1973;107(2):240–244.4685581
   PubMedGoogle Scholar
• Tauber M, Bal E, Pei XY, et al. IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol. 2016;136(9):1811–1819. doi:10.1016/j.jid.2016.04.03827220475
   PubMed Web of Science ®Google Scholar
• Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;7:51–63. doi:10.2147/PTT.S12628129387608
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2018;143(3):1021–1026.30036598
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–1369. doi:10.1038/jid.2012.49023303454
   PubMed Web of Science ®Google Scholar
• Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187–192. doi:10.1016/j.jdermsci.2014.02.00624656634
   PubMed Web of Science ®Google Scholar
• Liang J, Huang P, Li H, et al. Mutations in IL36RN are associated with geographic tongue. Hum Genet. 2017;136(2):241–252. doi:10.1007/s00439-016-1750-y27900482
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94(5):790–797. doi:10.1016/j.ajhg.2014.04.00524791904
   PubMed Web of Science ®Google Scholar
• Mossner R, Frambach Y, Wilsmann-Theis D, et al. palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Invest Dermatol. 2015;135(10):2538–2541. doi:10.1038/jid.2015.18625989471
   PubMed Web of Science ®Google Scholar
• Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol. 2013;133(11):2634–2637. doi:10.1038/jid.2013.21423648549
   PubMed Web of Science ®Google Scholar
• Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol. 2015;135(12):2964–2970. doi:10.1038/jid.2015.28826203641
   PubMed Web of Science ®Google Scholar
• Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784–795. doi:10.1016/j.ajhg.2012.03.01222521418
   PubMed Web of Science ®Google Scholar
• Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755–1757. doi:10.1038/jid.2014.4624476623
   PubMed Web of Science ®Google Scholar
• Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2251–2259. doi:10.1016/j.jid.2016.06.61827388993
   PubMed Web of Science ®Google Scholar
• Mossner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740–748. doi:10.1111/bjd.1586728887889
   PubMed Web of Science ®Google Scholar
• Alorainy M, Alshaya M, Al-Rikabi A, Ayesh M, Alsaif F. Acrodermatitis continua of Hallopeau with bone resorption in an 8-year-old patient: a case report. Case Rep Dermatol. 2017;9(3):259–264. doi:10.1159/00048537029422844
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim HL, Suh HY, et al. A case of acrodermatitis continua accompanying with osteolysis and atrophy of the distal phalanx that evoluted into generalized pustular psoriasis. Ann Dermatol. 2016;28(6):794–795. doi:10.5021/ad.2016.28.6.79427904292
   PubMed Web of Science ®Google Scholar
• Okuno H, Ogura K, Okuyama R, Itoi E. Two cases of acrodermatitis continua of Hallopeau associated with generalized arthritis. Acta Dermatovenerol Croat. 2013;21(4):265–267.24476617
   PubMed Web of Science ®Google Scholar
• Mueller RB, Ogilvie A, Schwarz S, Kern P, Schett G, Sticherling M. Adalimumab treatment of a patient with psoriasis suppurativa Hallopeau associated osteoarthropathy. Clin Exp Rheumatol. 2009;27:887.19917179
   PubMed Web of Science ®Google Scholar
• Kirkup ME, Lovell CR. Acquired syndactyly secondary to acrodermatitis continua of Hallopeau. Br J Dermatol. 2005;152:1083–1084. doi:10.1111/j.1365-2133.2005.06580.x15888186
   PubMed Web of Science ®Google Scholar
• Sadlier M. Acrodermatitis continua of Hallopeau and geographic tongue are variants of pustular psoriasis. JAAD Case Rep. 2018;4(3):277. doi:10.1016/j.jdcr.2017.08.02229687071
   PubMedGoogle Scholar
• Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80(12):771–793. doi:10.1111/j.1365-2133.1968.tb11947.x4236712
   PubMed Web of Science ®Google Scholar
• Ranugha PS, Kumari R, Thappa DM. Acrodermatitis continua of hallopeau evolving into generalised pustular psoriasis. Indian J Dermatol. 2013;58(2):161. doi:10.4103/0019-5154.108096
   PubMedGoogle Scholar
• Pearson LH, Allen BS, Smith JG Jr. Acrodermatitis continua of Hallopeau: treatment with etretinate and review of relapsing pustular eruptions of the hands and feet. J Am Acad Dermatol. 1984;11(4 Pt 2):755–762.6491002
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Sharma S. Significance of Gram’s stain smear, potassium hydroxide mount, culture, and microscopic pathology in the diagnosis of acrodermatitis continua of Hallopeau. Skinmed. 2011;9(4):260–261.21980714
   PubMedGoogle Scholar
• Sotiriadis D, Patsatsi A, Sotiriou E, Papagaryfallou I, Chrysomallis F. Acrodermatitis continua of Hallopeau on toes successfully treated with a two-compound product containing calcipotriol and betamethasone dipropionate. J Dermatolog Treat. 2007;18(5):315–318. doi:10.1080/0954663070136711817852633
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol. 2001;144(5):1000–1005. doi:10.1046/j.1365-2133.2001.04189.x11359388
   PubMed Web of Science ®Google Scholar
• Mozzanica N, Cattaneo A. The clinical effect of topical calcipotriol in acrodermatitis continua of hallopeau. Br J Dermatol. 1998;138(3):556. doi:10.1046/j.1365-2133.1998.02034.x
   Web of Science ®Google Scholar
• Emtestam L, Weden U. Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol. Br J Dermatol. 1996;135(4):644–646.8915165
   PubMed Web of Science ®Google Scholar
• Brill TJ, Elshorst-Schmidt T, Valesky EM, Kaufmann R, Thaci D. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology. 2005;211(4):351–355. doi:10.1159/00008850716286746
   PubMed Web of Science ®Google Scholar
• Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110(5):735–736.4418256
   PubMedGoogle Scholar
• Tsuji T, Sugai T. Topically administered fluorouracil in psoriasis. Arch Dermatol. 1972;105(2):208–212.5060863
   PubMedGoogle Scholar
• Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T, Novak N. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol. 2004;150(6):1194–1197. doi:10.1111/j.1365-2133.2004.05992.x15214910
   PubMed Web of Science ®Google Scholar
• van Dooren-Greebe RJ, van de Kerkhof PC, Chang A, Happle R. Acitretin monotherapy in acrodermatitis continua Hallopeau. Acta Derm Venereol. 1989;69(4):344–346.2568060
   PubMed Web of Science ®Google Scholar
• Slawsky LD, Libow LF. Successful treatment of acrodermatitis continua of Hallopeau with etretinate. J Am Acad Dermatol. 1990;23(6 Pt 1):1176–1178.2273128
   PubMed Web of Science ®Google Scholar
• Zachariae H, Thestrup-Pedersen K. Ciclosporin A in acrodermatitis continua. Dermatologica. 1987;175(1):29–32.
   Google Scholar
• Harland CC, Kilby PE, Dalziel KL. Acrodermatitis continua responding to cyclosporin therapy. Clin Exp Dermatol. 1992;17(5):376–378.1458653
   PubMed Web of Science ®Google Scholar
• Peter RU, Ruzicka T, Donhauser G, Braun-Falco O. Acrodermatitis continua-type of pustular psoriasis responds to low-dose cyclosporine. J Am Acad Dermatol. 1990;23(3 Pt 1):515–516.2212157
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Yeung J. Short- and long-term management of an acute pustular psoriasis flare: a case report. J Cutan Med Surg. 2017;21(5):452–456. doi:10.1177/120347541771249928535721
   PubMed Web of Science ®Google Scholar
• Rubio C, Martin MA, Arranz Sanchez DM, Vidaurrazaga C, Casado M. Excellent and prolonged response to infliximab in a case of recalcitrant acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2009;23:707–708. doi:10.1111/j.1468-3083.2008.02998.x18785890
   PubMed Web of Science ®Google Scholar
• Chowdhury MM, Motley RJ. Treatment of acrodermatitis continua of Hallopeau with oral propylthiouracil and methotrexate. Clin Exp Dermatol. 2001;26(8):657–660.11722449
   PubMed Web of Science ®Google Scholar
• Sakanoue M, Takeda K, Kawai K, Kanekura T. Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis, and associated arthropathy. Ther Apher Dial. 2013;17(5):477–483. doi:10.1111/1744-9987.1211324107275
   PubMed Web of Science ®Google Scholar
• Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for pustular psoriasis. Ther Apher Dial. 2008;12(1):13–18. doi:10.1111/j.1744-9987.2007.00536.x18257807
   PubMed Web of Science ®Google Scholar
• Shukuya R, Hasegawa T, Niwa Y, Okuma K, Ikeda S. Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis. J Dermatol. 2011;38(12):1130–1134. doi:10.1111/j.1346-8138.2011.01279.x22007872
   PubMed Web of Science ®Google Scholar
• Kanekura T, Hiraishi K, Kawahara K, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by activated neutrophils and psoriatic arthritis: evidence that GCAP removes Mac-1-expressing neutrophils. Ther Apher Dial. 2006;10(3):247–256. doi:10.1111/j.1744-9987.2006.00369.x16817789
   PubMed Web of Science ®Google Scholar
• Iijima S, Okazaki Y, Watanabe S, Maruyama Y. Case of acrodermatitis continua of Hallopeau following psoriasis with atypical clinical presentation. J Dermatol. 2014;41(11):1006–1008. doi:10.1111/1346-8138.1263925346303
   PubMed Web of Science ®Google Scholar
• Hjorth N, Thomsen K. Parakeratosis pustulosa. Br J Dermatol. 1967;79(10):527–532. doi:10.1111/j.1365-2133.1967.tb11407.x6061563
   PubMed Web of Science ®Google Scholar
• Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat. 2018;29(4):353–363. doi:10.1080/09546634.2017.139579829098909
   PubMed Web of Science ®Google Scholar
• Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy. Pediatr Dermatol. 2009;26(1):105–106. doi:10.1111/j.1525-1470.2008.00838.x19250426
   PubMed Web of Science ®Google Scholar
• Mang R, Ruzicka T, Stege H. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade). Br J Dermatol. 2004;150:379–380. England. doi:10.1111/j.1365-2133.2003.05761.x14996123
   PubMed Web of Science ®Google Scholar
• Ahmad K, Rogers S. Three years’ experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol. 2006;31(5):630–633. doi:10.1111/j.1365-2230.2006.02170.x16901301
   PubMed Web of Science ®Google Scholar
• Tobin AM, Kirby B. Successful treatment of recalcitrant acrodermatitis continua of Hallopeau with adalimumab and acitretin. Br J Dermatol. 2005;153:445–446. doi:10.1111/j.1365-2133.2005.06759.x16086767
   PubMed Web of Science ®Google Scholar
• Ryan C, Collins P, Kirby B, Rogers S. Treatment of acrodermatitis continua of Hallopeau with adalimumab. Br J Dermatol. 2009;160:203–205. doi:10.1111/j.1365-2133.2008.08893.x18945314
   PubMed Web of Science ®Google Scholar
• Lefkir S, Slimani S, Brahimi N, Ladjouze-Rezig A. Successful treatment of Acrodermatitis continua of Hallopeau associated with psoriatic arthritis with adalimumab. Eur J Rheumatol. 2015;2(2):78–79. doi:10.5152/eurjrheum.2015.007227708932
   PubMedGoogle Scholar
• Di Costanzo L, Napolitano M, Patruno C, Cantelli M, Balato N. Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab. J Dermatolog Treat. 2014;25(6):489–494. doi:10.3109/09546634.2013.84825924215490
   PubMed Web of Science ®Google Scholar
• Sopkovich JA, Anetakis Poulos G, Wong HK. Acrodermatitis continua of hallopeau successfully treated with adalimumab. J Clin Aesthet Dermatol. 2012;5(2):60–62.22468174
   PubMedGoogle Scholar
• Thielen AM, Barde C, Marazza G, Saurat JH. Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade). Dermatology. 2008;217(2):137–139. doi:10.1159/00013461318503258
   PubMed Web of Science ®Google Scholar
• Bonish B, Rashid RM, Swan J. Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? J Drugs Dermatol. 2006;5(9):903–904.17039659
   PubMedGoogle Scholar
• Nikkels AF, Pierard GE. Etanercept and recalcitrant acrodermatitis continua of Hallopeau. J Drugs Dermatol. 2006;5(8):705–706.
   Google Scholar
• Kazinski K, Joyce KM, Hodson D. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau. J Drugs Dermatol. 2005;4(3):360–364.15898294
   PubMedGoogle Scholar
• Puig L, Barco D, Vilarrasa E, Alomar A. Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review. Dermatology. 2010;220(2):154–158. doi:10.1159/00027741520110631
   PubMed Web of Science ®Google Scholar
• Silpa-archa N, Wongpraparut C. A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept. J Med Assoc Thai. 2011;94(9):1154–1157.21970208
   PubMedGoogle Scholar
• Balestri R, Rech G, Tasin L, Rizzoli L, Girardelli CR. Acrodermatitis continua of Hallopeau successfully treated with secukinumab. J Dermatolog Treat. 2018;29:1–7.
   Web of Science ®Google Scholar
• Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3(3):215–218. doi:10.1016/j.jdcr.2017.02.01628443313
   PubMedGoogle Scholar
• Herrero-Moyano M, Capusan TM, Martinez-Mera C, Llamas-Velasco M, Dauden E. Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab. JAAD Case Rep. 2018;4(8):842–844. doi:10.1016/j.jdcr.2018.03.01630246137
   PubMedGoogle Scholar
• Adisen E, Ozer I, Temel B, Gurer MA. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents. Dermatol Ther. 2017;30:2. doi:10.1111/dth.12460
   Web of Science ®Google Scholar
• Saunier J, Debarbieux S, Jullien D, Garnier L, Dalle S, Thomas L. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology. 2015;230(2):97–100. doi:10.1159/00036769025471551
   PubMed Web of Science ®Google Scholar
• Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol. 2012;148(3):297–299. doi:10.1001/archdermatol.2011.247322431771
   PubMedGoogle Scholar
• Ganesan R, Raymond EL, Mennerich D, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs. 2017;9(7):1143–1154. doi:10.1080/19420862.2017.135385328726542
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983. doi:10.1056/NEJMc181131730855749
   PubMed Web of Science ®Google Scholar